Company Profile

VDDI Inc (AKA: Virtual Drug Development Inc~VDDI Pharmaceuticals)
Profile last edited on: 4/19/2018      CAGE: 1XNQ5      UEI: EMZPARQCBHD4

Business Identifier: NO Business Identifier is currently available for this company.
Year Founded
1999
First Award
2000
Latest Award
2014
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

115 Penn Warren Drive Suite 300-389
Brentwood, TN 37027
Location: Multiple
Congr. District: 05
County: Williamson

Public Profile

Virtual Drug Development Inc. (aka VDDI) works in drug development, focusing on product opportunities where general proof-of-principle has already been established in pre-clinical or human testing, and where the products are novel and offer significant potential advantages to products currently in the market or in development. An Internet-based company, the firm's business model organizes around in-licensing and development of therapeutics indications in the areas of infectious disease, cancer, and cardiovascular disease. Product development areas include acute coronary syndrome, PCI, antifungal, antimicrobial, anthrax, NAD synthetase inhibitors for anthrax infections, agro-terrorism, new peptide pharmaceuticals announcement and InterLink, and biotechnologies. The firm is structured to pursue fast track approval for drugs in the areas of cancer, cardiovascular disease and infectious disease. Utilizing electronic data capture and data submission to regulatory authorities, the firm is headquartered in Tennessee,VDDI also has offices in Huntsville, AL; Ann Arbor, MIand Research Triangle Park,NC

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
1-4

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2014 1 NIH $374,051
Project Title: Development of Compounds for the Prevention and Treatment of Rhabdomyolysis
2000 1 NIH $135,590
Project Title: In Vitro Deliverability of Anti-Anthrax Discovery Leads

Key People / Management

  R Stephen Porter -- CEO, President and Founder

  Li Z Barber -- Vice President

  Kristen K Flaharty -- VP Regulatory Affairs & Co-Founder

  Ho-Yin Lo -- Vice President, Synthetic Chemistry

  John Alexander Oates -- Vice President Clinical Pharmacology

  L Jackson Roberts -- Consultant and Advisor

Company News

There are no news available.